• PDF / 181,163 Bytes
• 2 Pages / 595.245 x 841.846 pts (A4) Page_size
• 9 Downloads / 211 Views

DOWNLOAD

REPORT

---

1 XS

Various toxicities: 13 case reports In a single center retrospective study of 1791 patients conducted between January 2005 and July 2018, 13 patients, including 1 man, aged 37–63 years [not all sexes stated] were described, who developed panhypogammaglobulinaemia, immunodeficiency or neutropenia following treatment with clozapine. Additionally, seven of these 13 patients experienced impaired vaccine response following the concomitant administration of clozapine, Hib-meningococcal-vaccine-group-C-conjugate or pneumococcal vaccine [dosages, routes and time to reactions onsets not stated; not all outcomes stated]. A 37-year-old patient (patient ID1) developed panhypogammaglobulinaemia and immunodeficiency following treatment with clozapine for schizophrenia-like illness. Additionally, the patient experienced impaired vaccine response following the concomitant administration of clozapine, Hib-meningococcal-vaccine-group-C-conjugate [Menitorix] and pneumococcal vaccine [Pneumovax II]. The patient had been receiving clozapine for schizophrenia-like illness for >4 years. The patient had received Hibmeningococcal-vaccine-group-C-conjugate and pneumococcal vaccine. The patient’s laboratory investigations indicated panhypogammaglobulinaemia and immunodeficiency, which were considered secondary to the use of clozapine. The patient had recurrent respiratory tract infections (12 per year) and had undergone chest drain insertions due to loculated effusions. Postvaccination, the values of Hib-IgG titre and pneumococcus IgG titre were suggestive of impaired vaccine response following the concomitant administration of clozapine, Hib-meningococcal-vaccine-group-C-conjugate and pneumococcal vaccine. The patient received unspecified antibiotics and immunoglobulin replacement therapy. The patient’s therapy with clozapine was continued. A 63-year-old patient (patient ID2) developed panhypogammaglobulinaemia, neutropenia and immunodeficiency following treatment with clozapine for schizophrenia-like illness. The patient had been receiving clozapine for schizophrenia-like illness for 7.5 years. The patient had received Hib-meningococcal-vaccine-group-C-conjugate [Menitorix] and pneumococcal vaccine [Pneumovax II]. The patient’s laboratory investigations indicated panhypogammaglobulinaemia and immunodeficiency, which were considered secondary to the use of clozapine. The patient had persistent cough for over a year (productive of green sputum) despite several courses of unspecified antibiotics. The patient’s sputum was found to be positive for Haemophilus influenza B virus. The patient’s therapy with clozapine was discontinued due to neutropenia. The patient received unspecified antibiotics and immunoglobulin replacement therapy, following which the patient’s serum IgM level increased to 0.86 g/L from 0.22 g/L; however, IgA level remained below 0.24 g/L. A 46-year-old patient (patient ID3) developed panhypogammaglobulinaemia and immunodeficiency following treatment with clozapine for schizophrenia-like illness. The patient had been re